Pharsight

Tauvid patents expiration

TAUVID's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8932557 AVID RADIOPHARMS INC Imaging agents for detecting neurological dysfunction
May, 2032

(8 years from now)

Tauvid is owned by Avid Radiopharms Inc.

Tauvid contains Flortaucipir F-18.

Tauvid has a total of 1 drug patent out of which 0 drug patents have expired.

Tauvid was authorised for market use on 28 May, 2020.

Tauvid is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Tauvid from 28 May, 2024.

The generics of Tauvid are possible to be released after 26 May, 2032.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLORTAUCIPIR F-18 ingredient

NCE-1 date: 28 May, 2024

Market Authorisation Date: 28 May, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

TAUVID family patents

Family Patents